• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Jonathan Avery Explains How Substance Use Affects the Care of Patients With Mental Illness

Video

Jonathan Avery, MD, director of addiction psychiatry, New York-Presbyterian Hospital, Weill Cornell Medical Center, discussed how some psychiatrists will back away when treating a patient with co-occurring substance use and mental illness, when instead they should be leaning in to deliver evidence-based treatment.

Jonathan Avery, MD, director of addiction psychiatry, New York-Presbyterian Hospital, Weill Cornell Medical Center, discussed how some psychiatrists will back away when treating a patient with co-occurring substance use and mental illness, when instead they should be leaning in to deliver evidence-based treatment.

Transcript

How do concurrent substance use disorders affect how psychiatrists treat patients with mental illnesses?

Our hope is that co-occurring disorders cause a psychiatrist to lean in and offer all the evidence-based treatments. I think in practice what happens is that we tend to back out of the room when it looks like a complicated patient has multiple diagnoses, especially substance use disorders, and I think we tend to undertreat or refer out and not treat ourselves. And part of that is stigma-related, I think it’s been shown repeatedly that doctors have worse attitudes towards patients with co-occurring disorders than towards more simple cases. We really want them to not do non—evidence-based things, to not sort of back away but really to offer all the evidence-based treatments for the different diagnoses that they have.

Related Videos
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.